Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005–11. https://doi.org/10.1016/S0140-6736(06)69208-8.

Article  PubMed  Google Scholar 

Otto CM, Newby DE, Hillis GS. Calcific aortic stenosis: A review. JAMA. 2024;332(23):2014–26. https://doi.org/10.1001/jama.2024.16477.

Article  CAS  PubMed  Google Scholar 

Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: A report of the American college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation. 2021;143(5):e72–227. https://doi.org/10.1161/CIR.0000000000000923.

Article  PubMed  Google Scholar 

Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Elevated lipoprotein (a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol. 2014;63(5):470–7.

Article  CAS  PubMed  Google Scholar 

Arsenault BJ, Boekholdt SM, Dubé M-P, Rhéaume É, Wareham NJ, Khaw K-T, et al. Lipoprotein (a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case–control cohort. Circulation: Cardiovasc Genet. 2014;7(3):304–10.

CAS  Google Scholar 

Duarte Lau F, Giugliano RP. Lipoprotein(a) and its significance in cardiovascular disease: A review. JAMA Cardiol. 2022;7(7):760–9. https://doi.org/10.1001/jamacardio.2022.0987.

Article  PubMed  Google Scholar 

Tsamoulis D, Siountri I, Rallidis LS. Lipoprotein(a): its association with calcific aortic valve stenosis, the emerging RNA-Related treatments and the hope for a new era in treating aortic valve calcification. J Cardiovasc Dev Dis. 2023;10(3). https://doi.org/10.3390/jcdd10030096.

Pantelidis P, Oikonomou E, Lampsas S, Zakynthinos GE, Lysandrou A, Kalogeras K, et al. Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis. Cardiovasc Res. 2023;119(8):1641–55. https://doi.org/10.1093/cvr/cvad062.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng KH, Tsimikas S, Pawade T, Kroon J, Jenkins WS, Doris MK, et al. Lipoprotein (a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol. 2019;73(17):2150–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaiser Y, Singh SS, Zheng KH, Verbeek R, Kavousi M, Pinto S-J, et al. Lipoprotein (a) is robustly associated with aortic valve calcium. Heart. 2021;107(17):1422–8.

Article  CAS  PubMed  Google Scholar 

Kaiser Y, Daghem M, Tzolos E, Meah MN, Doris MK, Moss AJ, et al. Association of lipoprotein (a) with atherosclerotic plaque progression. J Am Coll Cardiol. 2022;79(3):223–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Capoulade R, Yeang C, Chan KL, Pibarot P, Tsimikas S. Association of mild to moderate aortic valve stenosis progression with higher lipoprotein (a) and oxidized phospholipid levels: secondary analysis of a randomized clinical trial. JAMA Cardiol. 2018;3(12):1212–7.

Article  PubMed  PubMed Central  Google Scholar 

Capoulade R, Chan Kwan L, Yeang C, Mathieu P, Bossé Y, Dumesnil Jean G, et al. Oxidized phospholipids, Lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol. 2015;66(11):1236–46. https://doi.org/10.1016/j.jacc.2015.07.020.

Article  CAS  PubMed  Google Scholar 

Kaltoft M, Langsted A, Afzal S, Kamstrup PR, Nordestgaard BG. Lipoprotein(a) and body mass compound the risk of calcific aortic valve disease. J Am Coll Cardiol. 2022;79(6):545–58. https://doi.org/10.1016/j.jacc.2021.11.043.

Article  CAS  PubMed  Google Scholar 

Capoulade R, Chan KL, Yeang C, Mathieu P, Bossé Y, Dumesnil JG, et al. Oxidized phospholipids, Lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol. 2015;66(11):1236–46. https://doi.org/10.1016/j.jacc.2015.07.020.

Article  CAS  PubMed  Google Scholar 

Tsimikas S. A test in context: Lipoprotein(a). J Am Coll Cardiol. 2017;69(6):692–711. https://doi.org/10.1016/j.jacc.2016.11.042.

Article  CAS  PubMed  Google Scholar 

Arsenault BJ, Loganath K, Girard A, Botezatu S, Zheng KH, Tzolos E, et al. Lipoprotein(a) and calcific aortic valve stenosis progression: A systematic review and Meta-Analysis. JAMA Cardiol. 2024. https://doi.org/10.1001/jamacardio.2024.1882.

Article  PubMed  Google Scholar 

Farina JM, Chao C-J, Pereyra M, Roarke M, Said EF, Barry T, et al. Role of lipoprotein(a) concentrations in bioprosthetic aortic valve degeneration. Heart. 2024;110(4):299–305. https://doi.org/10.1136/heartjnl-2023-322987.

Article  CAS  PubMed  Google Scholar 

Garg PK, Guan W, Karger AB, Steffen BT, Budoff M, Tsai MY. Lipoprotein (a) and risk for calcification of the coronary arteries, mitral valve, and thoracic Aorta: the multi-ethnic study of atherosclerosis. J Cardiovasc Comput Tomogr. 2021;15(2):154–60.

Article  PubMed  Google Scholar 

Masson W, Barbagelata L, Oberti P, Falconi M, Lavalle-Cobo A, Corral P, et al. High lipoprotein(a) levels and mitral valve disease: A systematic review. Nutr Metabolism Cardiovasc Dis. 2023;33(5):925–33. https://doi.org/10.1016/j.numecd.2023.01.025.

Article  CAS  Google Scholar 

Maloberti A, Fabbri S, Colombo V, Gualini E, Monticelli M, Daus F, et al. Lipoprotein(a): cardiovascular disease, aortic stenosis and new therapeutic option. Int J Mol Sci. 2022;24(1). https://doi.org/10.3390/ijms24010170.

Rodriguez GR, Bennett KR, Lehan PH. Calcification of the pulmonary valve. Chest. 1971;59(2):160–4.

Article  CAS  PubMed  Google Scholar 

Paslawska A, Tomasik PJ. Lipoprotein(a)-60 years Later-What do we know?? Cells. 2023;12(20). https://doi.org/10.3390/cells12202472.

Kaltoft M, Sigvardsen PE, Afzal S, Langsted A, Fuchs A, Kühl JT, et al. Elevated lipoprotein(a) in mitral and aortic valve calcification and disease: the Copenhagen general population study. Atherosclerosis. 2022;349:166–74. https://doi.org/10.1016/j.atherosclerosis.2021.11.029.

Article  CAS  PubMed  Google Scholar 

Bella JN, Tang W, Kraja A, Rao DC, Hunt SC, Miller MB, et al. Genome-wide linkage mapping for valve calcification susceptibility loci in hypertensive sibships: the hypertension genetic epidemiology network study. Hypertension. 2007;49(3):453–60.

Article  CAS  PubMed  Google Scholar 

Schnitzler JG, Ali L, Groenen AG, Kaiser Y, Kroon J. Lipoprotein (a) as orchestrator of calcific aortic valve stenosis. Biomolecules. 2019;9(12):760.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid Lowering with Rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of Rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121(2):306–14.

Article  CAS  PubMed  Google Scholar 

Bull S, Loudon M, Francis JM, Joseph J, Gerry S, Karamitsos TD, et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril in aortic stenosis (RIAS trial). Eur Heart Journal–Cardiovascular Imaging. 2015;16(8):834–41.

Article  Google Scholar 

Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352(23):2389–97.

Article  CAS  PubMed  Google Scholar 

Pawade TA, Doris MK, Bing R, White AC, Forsyth L, Evans E, et al. Effect of denosumab or alendronic acid on the progression of aortic stenosis: a double-blind randomized controlled trial. Circulation. 2021;143(25):2418–27.

Article  CAS  PubMed  PubMed Central